We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Read MoreHide Full Article
Key Takeaways
KROS is advancing rinvatercept for Duchenne muscular dystrophy, with a phase II study set to start in 2026.
Keros Therapeutics received FDA orphan drug designation for rinvatercept for DMD in August 2025
Keros Therapeutics halted cibotercept development to focus resources on rinvatercept's neuromuscular programs.
Keros Therapeutics (KROS - Free Report) is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins.
Rinvatercept, KROS’ lead pipeline candidate, is engineered to selectively bind and inhibit TGF-β ligands, including myostatin (GDF8) and activin A, which are key negative regulators of muscle and bone mass and strength. By blocking these pathways, the company believes KER-065 has the potential to promote skeletal muscle regeneration, increase muscle size and strength, reduce body fat and muscle fibrosis, and enhance overall bone strength.
Keros Therapeutics is advancing rinvatercept for the treatment of neuromuscular disorders, initially targeting Duchenne muscular dystrophy (DMD).
According to Keros, glucocorticoids — the current standard of care for DMD — are associated with significant long-term side effects, including muscle catabolism, increased fat accumulation and accelerated bone loss.
In August 2025, it announced that the FDA granted orphan drug designation for KER-065 for the treatment of DMD.
KROS plans to begin a phase II trial in patients with DMD in the first quarter of 2026. Last year, the company reported initial top-line results from a phase I study of KER-065 in healthy volunteers.
KROS is also developing for the treatment of amyotrophic lateral sclerosis (ALS). The company plans to engage with regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in patients with ALS.
Keros Therapeutics was previously advancing cibotercept for pulmonary arterial hypertension, but in August 2025, it discontinued the program and redirected resources toward rinvatercept, which currently appears to offer more compelling potential.
KROS’ Competition in the DMD Space
DMD is a particularly competitive and complex therapeutic area. At present, many DMD patients are treated with corticosteroids to manage the inflammatory component of the disease.
Sarepta Therapeutics (SRPT - Free Report) is a formidable player in this space with a strong DMD franchise that includes exon-skipping therapies, such as Exondys 51, Vyondys 53 and Amondys 45. In June 2023, Sarepta obtained accelerated approval from the FDA for Elevidys, an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients aged four to five years with DMD with a confirmed mutation in the DMD gene.
Thereafter, in June 2024, the FDA granted full approval to Elevidys for the treatment of ambulatory individuals aged four years and older, and accelerated approval for the treatment of non-ambulatory individuals aged four years and older.
In July 2025, Sarepta temporarily paused U.S. shipments after reports of fatal liver injury but resumed distribution for ambulatory patients after the FDA indicated the pause could be lifted.
PTC Therapeutics, Inc. (PTCT - Free Report) currently markets Emflaza (deflazacort) for the treatment of DMD.
Emflaza is approved in the United States for the treatment of DMD in patients two years and older.
PTCT’s other DMD drug, Translarna, has marketing authorization in Russia for the treatment of nonsense mutation DMD (nmDMD) in patients aged two years and older, and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and with continued treatment allowed if patients become nonambulatory, as well as in various other countries.
PTC Therapeutics held a conditional marketing authorization for Translarna in the European Economic Area (EEA), subject to annual EMA review. Despite submitting additional clinical data and requests to convert to full approval and renew the authorization, the EMA’s CHMP issued repeated negative opinions. In March 2025, the European Commission adopted the CHMP’s decision not to renew Translarna’s authorization for nmDMD.
KROS’ Price Performance, Valuation & Estimates
Shares of KROS have gained 2.9% in the past year compared with the industry’s rise of 15.9%.
Image Source: Zacks Investment Research
Going by the price/book ratio, KROS is quite inexpensive. Its shares currently trade at 0.51x tangible book value, lower than the industry’s average of 3.76X and its mean of 3.91X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share is unchanged at $3.36 in the past seven days and is pegged at $4.34 for 2027.
View the Zacks #1 Rank List
Image: Bigstock
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Key Takeaways
Keros Therapeutics (KROS - Free Report) is focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins.
Rinvatercept, KROS’ lead pipeline candidate, is engineered to selectively bind and inhibit TGF-β ligands, including myostatin (GDF8) and activin A, which are key negative regulators of muscle and bone mass and strength. By blocking these pathways, the company believes KER-065 has the potential to promote skeletal muscle regeneration, increase muscle size and strength, reduce body fat and muscle fibrosis, and enhance overall bone strength.
Keros Therapeutics is advancing rinvatercept for the treatment of neuromuscular disorders, initially targeting Duchenne muscular dystrophy (DMD).
According to Keros, glucocorticoids — the current standard of care for DMD — are associated with significant long-term side effects, including muscle catabolism, increased fat accumulation and accelerated bone loss.
In August 2025, it announced that the FDA granted orphan drug designation for KER-065 for the treatment of DMD.
KROS plans to begin a phase II trial in patients with DMD in the first quarter of 2026. Last year, the company reported initial top-line results from a phase I study of KER-065 in healthy volunteers.
KROS is also developing for the treatment of amyotrophic lateral sclerosis (ALS). The company plans to engage with regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in patients with ALS.
Keros Therapeutics was previously advancing cibotercept for pulmonary arterial hypertension, but in August 2025, it discontinued the program and redirected resources toward rinvatercept, which currently appears to offer more compelling potential.
KROS’ Competition in the DMD Space
DMD is a particularly competitive and complex therapeutic area. At present, many DMD patients are treated with corticosteroids to manage the inflammatory component of the disease.
Sarepta Therapeutics (SRPT - Free Report) is a formidable player in this space with a strong DMD franchise that includes exon-skipping therapies, such as Exondys 51, Vyondys 53 and Amondys 45. In June 2023, Sarepta obtained accelerated approval from the FDA for Elevidys, an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients aged four to five years with DMD with a confirmed mutation in the DMD gene.
Thereafter, in June 2024, the FDA granted full approval to Elevidys for the treatment of ambulatory individuals aged four years and older, and accelerated approval for the treatment of non-ambulatory individuals aged four years and older.
In July 2025, Sarepta temporarily paused U.S. shipments after reports of fatal liver injury but resumed distribution for ambulatory patients after the FDA indicated the pause could be lifted.
PTC Therapeutics, Inc. (PTCT - Free Report) currently markets Emflaza (deflazacort) for the treatment of DMD.
Emflaza is approved in the United States for the treatment of DMD in patients two years and older.
PTCT’s other DMD drug, Translarna, has marketing authorization in Russia for the treatment of nonsense mutation DMD (nmDMD) in patients aged two years and older, and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and with continued treatment allowed if patients become nonambulatory, as well as in various other countries.
PTC Therapeutics held a conditional marketing authorization for Translarna in the European Economic Area (EEA), subject to annual EMA review. Despite submitting additional clinical data and requests to convert to full approval and renew the authorization, the EMA’s CHMP issued repeated negative opinions. In March 2025, the European Commission adopted the CHMP’s decision not to renew Translarna’s authorization for nmDMD.
KROS’ Price Performance, Valuation & Estimates
Shares of KROS have gained 2.9% in the past year compared with the industry’s rise of 15.9%.
Image Source: Zacks Investment Research
Going by the price/book ratio, KROS is quite inexpensive. Its shares currently trade at 0.51x tangible book value, lower than the industry’s average of 3.76X and its mean of 3.91X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 loss per share is unchanged at $3.36 in the past seven days and is pegged at $4.34 for 2027.
Image Source: Zacks Investment Research
KROS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.